Special ultrasound device approved for dense breasts

Share this article:

The FDA has approved the first ultrasound device for use in combination with standard mammography in women with dense breast tissue who have a negative mammogram and no symptoms of breast cancer. The somo-V Automated Breast Ultrasound System (ABUS), marketed by U-Systems Inc. (Sunnyvale, California), is approved for use in women who have not had previous surgery, biopsy, or other invasive procedures in the breast, as such interventions might alter the appearance of breast tissue on a sonogram.

According to National Cancer Institute (NCI) estimates cited by the FDA in announcing the ABUS approval, approximately 40% of women undergoing screening mammography have dense breasts. In contrast with less-dense breasts, which have a high amount of fatty tissue, dense breasts have a high amount of connective and glandular, or fibroglandular, tissue. Fibroglandular breast tissue appears as solid white areas on a mammogram, just as tumors do. As a result, dense breast tissue may obscure smaller tumors, potentially delaying cancer detection. Ultrasonography has been shown to be capable of detecting small masses in dense breasts.

The newly available ABUS has a specially shaped transducer that can automatically scan the entire breast in about 1 minute to produce several images for review. Before approving the ABUS, the FDA reviewed results from a clinical study in which radiologists were asked to review mammograms alone or in conjunction with the somo-v ABUS images for 200 women with dense breasts and negative mammograms. Biopsies were then performed on masses detected with the ultrasonography device. A statistically significant increase in breast cancer detection occurred when ABUS images were reviewed in conjunction with mammograms compared with when mammograms alone were reviewed.

As part of the FDA approval, the ABUS manufacturer is required to provide thorough training for physicians and technologists using the device, and must provide each facility with a manual that clearly defines system tests required for initial, periodic, and yearly quality-control measures.

 

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Calcium isotope analysis predicts myeloma progression

Researchers believe that a staple of Earth science research can be used in biomedical settings to predict the course of disease.

Biomarker for aggressive, basal-like breast cancer identified

A biomarker strongly linked to basal-like breast cancer has been identified.

Tumor suppressor mutations alone do not explain deadly cancer

Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.